secwatch.observer — SEC 8-K summary
======================================

Issuer:     Assertio Holdings, Inc. (ASRT)
CIK:        0001808665
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001808665-23-000049
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assertio Q2 sales up 13% to $40.1M; closes Spectrum buy; withdraws guidance on generic Indocin
--------------------------------------------------------------------------------

- Net product sales $40.1M (+13% YoY); GAAP net income $8.5M ($0.13 EPS), adjusted EPS $0.19 vs $0.28 YoY.
- Acquisition of Spectrum closed July 31; ROLVEDON Q2 sales $21.0M, launch trajectory strong.
- Cash from operations $18.6M; cash and equivalents $70.2M at quarter end.
- 2023 financial guidance withdrawn after FDA approval of generic indomethacin suppository.
- SG&A $16.8M, up from $10.5M, includes $3.4M transaction costs vs $2.0M insurance benefit last year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808665/000180866523000049/0001808665-23-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808665/000180866523000049/asrt-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001808665-23-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer